Document is current

Article History

Received: 22 July 2024

Accepted: 22 October 2024

First Online: 12 November 2024

Declarations

:

: Not applicable.

: JPP: founding member of AlphaKen, member of the Scientific Advisory board of PRECIRIX, research grants from PRECIRIX, ROCHE, ORANO and NH TherAguix; PMG: Immedica, advice on dosimetry procedures (personal fee); KH: consultant fees from: Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, Molecular Partners, NVision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, and Theragnostics, ymabs, research grants from: Advanced Accelerator Applications, a Novartis company, Boston Scientific, Janssen, stock or other ownership interests with: AdvanCell, Aktis Oncology, Convergent, NVision, Pharma 15, and Sofie Biosciences; DD: consultant fees Novartis, Telix, Immedica, Spectrum Dynamics; DT: Novartis Advisory Board (personal fees); FWBVL: nothing to disclose; JK: Novartis, Advisory Board (personal fee), GE Healthcare, Advisory Board (personal fee), Oncobeta (speaker's fee); UE: institutional grants from Novartis; ML: institutional grants from Ipsen, Nordic Nanovector, Novartis and PentixaPharm; KL: consultant fees from: Sofie Biosciences, Avidity Partners, research grants from: Mariana Oncology, Novartis, AMGEN, Debiopharm.